CAJ | 학술논문

COPD是常见的呼吸系统疾病。支气管舒张剂是控制COPD症状的主要药物，支气管扩张剂又分为β2-受体激动剂、抗胆碱药和茶碱类药物。临床研究表明，长效β2-激动剂+抗胆碱药、长效β2-激动剂+糖皮质激素合用有明显的控制COPD症状的作用，具有支气管舒张作用明显增强、作用持续时间长、不良反应减少等特点。近年来已经成为COPD治疗药物研究开发的热点之一。本文就其作用机制、国外上市开发现状、国外销售情况及国内研究开发进展等进行综述。
COPD시상견적호흡계통질병。지기관서장제시공제COPD증상적주요약물，지기관확장제우분위β2-수체격동제、항담감약화다감류약물。림상연구표명，장효β2-격동제+항담감약、장효β2-격동제+당피질격소합용유명현적공제COPD증상적작용，구유지기관서장작용명현증강、작용지속시간장、불량반응감소등특점。근년래이경성위COPD치료약물연구개발적열점지일。본문취기작용궤제、국외상시개발현상、국외소수정황급국내연구개발진전등진행종술。
Chronic obstructive pulmonary disease (COPD) is a common disease of respiratory system. Bronchodilators are the main drugs to control the symptoms of COPD, and can be divided intoβ2-agonists, anticholinergic agents and theophylline drugs. Long-acting β2-agonists in combination with either anticholinergic agents or glucocorticoid can obviously control the symptoms of COPD, which possess such characteristics as the remarkable enhancement of bronchodilatory effect, long duration of action, reduction of adverse reaction in clinical application and have become one of the hotpoints in research and development of drugs for the treatment of COPD. The mechanism, foreign development status, sales and domestic research progress of bronchodilators are reviewed.